Gentasoothe Topical Spray is Gentamicin sulfate with betamethasone valerate, a broad-spectrum antibiotic spray with anti-inflammatory and antipruritic action for the treatment of infected superficial lesions in dogs that are caused by bacteria susceptible to gentamicin.Add this item to your cart:
**Note: This product requires a veterinarian's prescription to purchase.At checkout you will need to provide your veterinarian's FAX or email address. We will then send him or her a prescription verification that he or she will need to sign and return before we can ship you this product.
Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Additionally, corticosteroids administered to dogs, rabbits and rodents during pregnancy have produced cleft palate. Other congenital anomalies, including deformed forelegs, phocomelia and anasarca, have been reported in offspring of dogs which received corticosteroids during pregnancy.
For the treatment of infected superficial lesions in dogs caused by bacteria susceptible to gentamicin.
If hypersensitivity of any of the components occurs, discontinue treatment and institute appropriate therapy.
DOSAGE AND ADMINISTRATION:
Prior to treatment, remove excessive hair and clean the lesion and adjacent area. Hold bottle upright 3 to 6 inches from the lesion and depress the sprayer head twice. Administer 2 to 4 times daily for 7 days. Each depression of the sprayer head delivers 0.7 mL of Gentamicin Sulfate With Betamethasone Valerate Topical Spray.
Gentamicin sulfate with betamethasone valerate topical spray was well-tolerated in an abraded skin study in dogs. No treatment-related toxicological changes in the skin were observed. Systemic effects directly related to treatment were confined to histological changes in the adrenals, liver and kidney and to organ-to-body weight ratios of adrenals. All were dose related, were typical for or not unexpected with corticosteroid therapy and were considered reversible with cessation of treatment.
POSSIBLE SIDE EFFECTS:
Side effects such as SAP and SGPT enzyme elevations, weight loss, anorexia, polydipsia and polyuria have occurred following parenteral or systemic use of synthetic corticosteroids in dogs. Vomiting and diarrhea occasionally bloody have been observed in dogs. Cushing&rsquos syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.
Antibiotic susceptibility of the pathogenic organisms should be determined prior to use of this preparation. Use of topical antibiotics may permit overgrowth of non-susceptible bacteria, fungi or yeasts. If this occurs, treatment should be instituted with other appropriate agents as indicated. Administration of recommended dose beyond 7 days may result in delayed wound healing. Animals treated longer than 7 days should be monitored closely. Avoid ingestion. Oral or parenteral use of corticosteroids, depending on dose, duration and specific steroid may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdrawn from systemic corticosteroids treatments, therapy with a rapidly acting corticosteroid should be considered in especially stressful situations. If ingestion should occur, patients should be closely observed for the usual signs of adrenocorticoid overdosage, which includes sodium retention, potassium loss, fluid retention, weight gains, polydipsia and/or polyuria. Prolonged use or overdosage may produce adverse immunosuppressive effects.
For Topical Use in Dogs
Only For Animal Use Only